Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting
... that data relating to
paroxysmal nocturnal
hemoglobinuria (PNH), as well as to Soliris(R)
(eculizumab), a ... in Patients with Paroxysmal Nocturnal
hemoglobinuria (PNH)" Dr. Peter Hillmen et al. -- ... Disease Burden in Paroxysmal Nocturnal
hemoglobinuria Patients with Lower Levels of Hemolysis, ...
Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
... Union in 2007 as a treatment for patients with paroxysmal nocturnal
hemoglobinuria ("PNH"), a rare, debilitating and life-threatening blood disease. The use ... is the first product approved for the treatment of paroxysmal nocturnal
hemoglobinuria (PNH) in the U.S. and Europe. PNH is a rare, debilitating, and ...
Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting
... (eculizumab) as a treatment for patients with paroxysmal
nocturnal
hemoglobinuria (PNH). Data also have been published regarding
initial experience with ... on Ferritin Homeostasis in Eculizumab Treated Paroxysmal Nocturnal
hemoglobinuria (PNH) Patients," Dr. Alexander Roeth, et al. Abstract: ...
Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)
... targets the immune system). Soliris(R), a humanized monoclonal
antibody, is approved in the U.S. and Europe as a treatment for paroxysmal
nocturnal
hemoglobinuria (PNH), a rare, debilitating and life-threatening
blood disease. The company is exploring the use of Soliris(R) as a
treatment for patients with other ...
Hemoglobinuria in Medical Technology
PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
... a rare blood disorder called
paroxysmal nocturnal
hemoglobinuria (PNH), including those who might have
been ... Disease Burden in Paroxysmal
Nocturnal
hemoglobinuria Patients with Lower Levels of Hemolysis, ... Disease Burden in Paroxysmal Nocturnal
hemoglobinuria Patients with Lower Levels of Hemolysis, ...
Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH
... a rare
blood disorder called paroxysmal nocturnal
hemoglobinuria (PNH) were found
to be six times more likely than ... in Patients with
Paroxysmal Nocturnal
hemoglobinuria (PNH)" and "Sustained Improvements in
Transfusion ... cytometric analysis of paroxysmal nocturnal
hemoglobinuria in the United States and Japan. Medicine ...
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
... first therapy approved for paroxysmal nocturnal
hemoglobinuria (PNH), a
rare, debilitating and life-threatening ... cytometric analysis of paroxysmal nocturnal
hemoglobinuria in the United States and Japan. Medicine ... ischemic infarction in paroxysmal nocturnal
hemoglobinuria report of 2 cases and updated review of 7 ...
Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
... (eculizumab) treatment of Japanese
patients with paroxysmal nocturnal
hemoglobinuria (PNH). The pre-specified
primary efficacy endpoint of change in hemolysis ... A et al. The incidence and prevalence of
paroxysmal nocturnal
hemoglobinuria (PNH) and survival of patients
in Yorkshire [abstract]. Blood. ...
Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis
... fatigue and thrombosis with eculizumab treatment
in paroxysmal nocturnal
hemoglobinuria [abstract]. Blood. 2007;110
(11):1072a.
(11) Hill A, Platts PJ, Smith A et al. The incidence and prevalence of
paroxysmal nocturnal
hemoglobinuria (PNH) and survival of patients in
Yorkshire [abstract]. Blood. ...
Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
... as a treatment for Japanese
patients with paroxysmal nocturnal
hemoglobinuria (PNH). The open-label
study, which was authorized by Japan's ... Smith A et al. The incidence and prevalence of paroxysmal nocturnal
hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. ...
Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
... of patients with a rare
blood disorder called paroxysmal nocturnal
hemoglobinuria (PNH), according
to an analysis of the Phase III SHEPHERD study published ... PJ, Smith A et al. The incidence and prevalence of
paroxysmal nocturnal
hemoglobinuria (PNH) and survival of patients in
Yorkshire [abstract]. Blood. ...
First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting
... (eculizumab),
a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc.
(Nasdaq: ALXN ) for the treatment of paroxysmal nocturnal
hemoglobinuria (PNH),
was associated with an improvement in hematologic parameters in a limited
number of patients with two other rare and severe ...
Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
... N Engl J Med. 2006;355:1233-1243. (3) Hill A, Platts PJ, Smith A et al. The incidence and prevalence of paroxysmal nocturnal
hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. 2006;108(11):985. (4) Socie G, Mary J Yves, de Gramont A, et al. Paroxysmal ...
Hemoglobinuria in Medical Products
Paroxysmal Nocturnal Hemoglobinuria Profile-WBC
Description: ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' ...
Company:ARUP Laboratories
Paroxysmal Nocturnal Hemoglobinuria Profile-RBC
Description: ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' ...
Company:ARUP Laboratories
Hemoglobinuria in Medical Definition
Hematopathology
... stomatocytosis , Warm autoimmune hemolytic anemia , Hemolytic-uremic syndrome , Microangiopathic hemolytic anemia , Paroxysmal nocturnal
hemoglobinuria ) • Aplastic anemia : ( Acquired pure red cell aplasia , Fanconi anemia ) • Hemochromatosis
Coagulation / platelets
DIC • ...
Pathology
... stomatocytosis , Warm autoimmune hemolytic anemia , Hemolytic-uremic syndrome , Microangiopathic hemolytic anemia , Paroxysmal nocturnal
hemoglobinuria ) • Aplastic anemia : ( Acquired pure red cell aplasia , Fanconi anemia ) • Hemochromatosis
Coagulation / platelets
DIC • ...
Hemoglobinuria in Medical Dictionary
Hemoglobinuria
... Paroxysm al cold
hemoglobinuria is a condition where antibodies are formed ... blood group. Paroxysm al nocturnal
hemoglobinuria (PNH) Definition: Paroxysm al nocturnal
hemoglobinuria is a rare, acquired disorder of blood cells in ...
Paroxysm
... Paroxysm al nocturnal
hemoglobinuria (PNH) Definition: Paroxysm al nocturnal
hemoglobinuria is a rare, acquired disorder of blood cells in ... electrical impulses ... Paroxysm al cold
hemoglobinuria is a condition where antibodies are formed ...
Burns
... during major surgery , severe burns with fluid loss through burned skin , ... burns , kidney cancer , malaria , paroxysm al nocturnal
hemoglobinuria (dark urine in the morning that lightens up during the day), the hemolytic -uremic syndrome ( HUS ), pyelonephritis , sickle cell anemia ...
Glomerulonephritis
... 1 glomerulonephritis ; ... acute nephritis ( acute glomerulonephritis ), burns , kidney cancer , malaria , paroxysm al nocturnal
hemoglobinuria (dark urine in the morning that lightens up during the day), the hemolytic -uremic syndrome ( HUS ), pyelonephritis , ... The most common ...
Haptoglobin
... of hemoglobin in the blood rises above the ability of haptoglobin to reclaim it, hemoglobin begins to appear in the urine -- there is
hemoglobinuria . Los niveles de haptoglobin a srica pueden estar disminuidos Puede haber presencia de hemoglobin a en la orina Puede haber presencia de ...
Paronychia
... with paronychia . paronychia parotid duct parotid gland par otitis paroxysm al atria l tachycardia (pat) paroxysm al cold
hemoglobinuria paroxysm al nocturnal cephalgia paroxysm al nocturnal dyspnea paroxysm al supra ventricular tachycardia . paroxysm al tachycardia ... ...
Parkinsonism
... to ... parkinsonism paronychia parotid duct parotid gland par otitis paroxysm al atria l tachycardia (pat) paroxysm al cold
hemoglobinuria paroxysm al nocturnal cephalgia paroxysm al nocturnal dyspnea paroxysm al supra ventricular tachycardia . ...
More>>
Hemoglobinuria in Biological Technology
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
... first therapy approved for paroxysmal nocturnal
hemoglobinuria (PNH), a
rare, debilitating and life-threatening ... cytometric analysis of paroxysmal nocturnal
hemoglobinuria in the United States and Japan. Medicine ... ischemic infarction in paroxysmal nocturnal
hemoglobinuria report of 2 cases and updated review of 7 ...
Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
... on Ferritin Homeostasis
in Eculizumab Treated Paroxysmal Nocturnal
hemoglobinuria (PNH) Patients" was
presented yesterday at the ASH annual meeting by ... PJ, Smith A et al. The incidence and prevalence of
paroxysmal nocturnal
hemoglobinuria (PNH) and survival of patients in
Yorkshire [abstract]. Blood. ...
Alexion Reports Third Quarter 2008 Results
... 2007 and the European Commission (EC) in June 2007, is the only drug
specifically indicated for the treatment of patients with paroxysmal
nocturnal
hemoglobinuria ("PNH"), a rare, debilitating and life-threatening
blood disease.
The Company reports both GAAP operating results and non-GAAP operating
results. ...
Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
... be found at: http://www.alexionpharm.com .
[ALXN-G]
(1) Hill A, Platts PJ, Smith A et al. The incidence and prevalence of
paroxysmal nocturnal
hemoglobinuria (PNH) and survival of patients in
Yorkshire [abstract]. Blood. 2006;108(11):985.
(2) Socie G, Mary J Yves, de Gramont A, et al. Paroxysmal ...
Alexion Reports First Quarter 2008 Results
... and the European Commission (EC) in June 2007, is the only drug
specifically indicated for the treatment of patients with paroxysmal
nocturnal
hemoglobinuria ("PNH"), a rare, debilitating and life-threatening
blood disease.
The Company reports both GAAP results and non-GAAP results. Non-GAAP
results are ...
Alexion Reports Fourth Quarter and Full Year 2007 Results
... 2007 and the European Commission in June 2007, is the only drug
specifically indicated for the treatment of patients with paroxysmal
nocturnal
hemoglobinuria ("PNH"), a rare, debilitating and life-threatening
disease.
A portion of the Soliris product sold in the fourth quarter was
previously accounted ...
Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
... during 2007. Soliris(R) (eculizumab) is a complement inhibitor
product developed and marketed by Alexion for the treatment of paroxysmal
nocturnal
hemoglobinuria ("PNH"), a rare, debilitating and life-threatening
disease.
"Soliris opened a major new therapeutic avenue for patients with PNH,
and the ...